
Steven Ades MD
Professor, Medicine, University of Vermont College of Medicine
Join to view full profile
111 Colchester AveHematologyoncology ACC Level 2Burlington, VT 05401
Phone+1 802-847-8400
Dr. Ades is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
McGill University Faculty of MedicineClass of 1996
Certifications & Licensure
NY State Medical License 2024 - 2028
VT State Medical License 2007 - 2026
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Beacon Cancer Registry Reporting, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2013-2017
Clinical Trials
- Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
- Cisplatin, Irinotecan, and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer That Can Be Removed By Surgery
- Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2006 Sep 15
Publications & Presentations
PubMed
- Reply to: Real World Data and Survival: Bias Is Not Evidence.Karlyn A Martin, Chris E Holmes, Steven Ades
JCO Oncology Practice. 2026-10-16 - 1 citationsImpact of Venous Thrombosis Prevention in Ambulatory Oncology: Importance of Guideline Adherence.Chris E Holmes, Karlyn A Martin, Derek Devine, Jacob Barker, Peter W Callas
JCO Oncology Practice. 2026-04-06 - 4 citationsAbemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.Matthew Smith, Josep Piulats, Tilman Todenhöfer, Jae-Lyun Lee, José Arranz Arija
The Lancet. Oncology. 2025-11-01
Journal Articles
- Cost-Effectiveness of Prostate Radiation Therapy for Men with Newly Diagnosed Low-Burden Metastatic Prostate CancerNataniel H Lester-Coll, Steven Ades, James B Yu, JAMA Network Open
Press Mentions
UVM Cancer Center Advances Science Through Groundbreaking Clinical TrialsMay 19th, 2025
How to Prevent a Cyberattack from Derailing Cancer CareOctober 1st, 2021
Non-Operative Management and Early Response Assessment in Rectal Cancer (NOM-ERA)December 8th, 2023
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: